Committee report: nominations and bills advanced by Senate Health and Human Services

The Senate Health and Human Services Committee concluded a multi-item meeting that included confirmations, amendments and the advancement of several House bills. Below are the confirmed nominees and bills the committee recorded as advanced or passed during the session.

Confirmed nominations (committee votes):
- Shonda Lassiter to the State Board of Pharmacy — committee reported favorably (11 ayes, 0 nays).
- Dr. Lane Sebera to the Health Care Workforce Training Commission — reported favorably (12 ayes, 0 nays).
- Dr. Paul E. Wright to the Health Care Workforce Training Commission (unexpired term) — reported favorably (12 ayes, 0 nays).

Selected bills advanced or passed (committee votes):
- HB 37 67 (classify 14 fentanyl‑enhancing chemicals) — advanced (10 ayes, 0 nays).
- HB 39 34 (Board of Dentistry, workforce cleanup) — advanced (11 ayes, 0 nays).
- HB 41 99 (workforce pilot; eligibility amendment adopted) — advanced (9 ayes, 2 nays).
- HB 43 36 (interventional pain management updates) — passed (11 ayes, 0 nays).
- HB 29 47 (behavioral health clinical interns billing Medicaid) — advanced (10 ayes, 1 nay).
- HB 38 34 (ibogaine clinical trials authorization) — advanced (10 ayes, 2 nays).
- HB 43 02 (juvenile system oversight disclosure amendment adopted) — advanced (12 ayes, 0 nays).
- HB 40 95 (restate 2‑1‑1 advisory council) — advanced (11 ayes, 0 nays).
- HB 32 87 (DV and human trafficking signage in health facilities) — advanced (11 ayes, 0 nays).
- HB 36 49 (DMHSAS Real Property Trust changes) — passed (12 ayes, 0 nays).
- HB 44 30 and HB 44 31 (APRN/PA malpractice alignment and pharmacy act updates) — advanced (votes recorded as unanimous in committee).
- HB 20 59 (reimbursements for medications for detained people) — passed (12 ayes, 0 nays).
- HB 36 47 (all‑payer claims database; transparency board) — passed (10 ayes, 2 nays).

Committee action notes: many measures were characterized as technical cleanups, workforce supports, or authorizations for further study; House Bill 38 34 (ibogaine) received the most extended testimony and questioning. Committee members indicated some bills will require follow-up clarifications on operational details or funding sources before floor consideration.

The committee adjourned and signaled plans to meet again next week.